Molecular Zip Code based therapeutics to better treat Neurological Diseases
AivoCode is an emerging biotech startup pioneering the development of innovative and broad platform technologies to improve the treatment and management of neurological diseases such as brain injury, Alzheimer’s disease and other neurodegenerative disorders. AivoCode’s technology is based on identifying molecular “zip codes” specific to diseased regions or cell types in the brain.
Our Technology
Traumatic Brain Injury
Traumatic brain injury (TBI) is the leading cause of death and disability in adults over 50 and impacts over 2.5 million people annually in the US. Current treatment options often involve invasive surgeries or direct injection into the CNS, which can be imprecise, inefficient, imperfectly timed and associated with undesirable side effects. AivoCode is developing a novel, molecular zip code based proprietary therapeutic to reduce the secondary injury following TBI to improve outcomes of in these patients.
Neurodegenerative Diseases
Alzheimer’s disease (AD) is the most common progressive neurodegenerative disorder associated with aging. Limited success of recent clinical trials of various AD treatments may be attributable to treating the disease too late. AivoCode is looking beyond amyloid in AD and has identified an unexplored target present early in AD blood vessels. AivoCode is now developing therapeutic antibodies to inhibit this target for an early therapeutic intervention.
Our Team
Meet our team of world class Scientists & Thought Leaders
News
Learn more about our Discoveries & Awards
Get in Touch
We’d love to hear from you